Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD
Recruiting
Observational Study
Colo-rectal Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 45 – 75
- Sex
- Any
- Study type
- Observational
- Participants needed
- 600 (estimated)
- Sponsor
- Epiliquid Holding, Inc · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methyl…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Candidate for colonoscopy or colorectal surgery
* Willing and able to provide informed consent
* Able to provide blood and/or tissue sample before treatment or resection
Exclusion Criteria:
* Prior history of colorectal cancer
* Inflammatory bowel disease
* Known hereditary …
Contacts